Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
Open accessPublished version of a preprint
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Mapping antibody escape in SARS-CoV-2: Several antibodies are in use or under development as therapies to treat COVID-19. As new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants emerge, it is important to predict whether they will remain susceptible to antibody treatment. Starr et al. used a yeast library that covers all mutations to the SARS-CoV-2 receptor-binding domain that do not strongly disrupt binding to the host receptor (ACE2) and mapped how these mutations affect binding to three leading anti–SARS-CoV-2 antibodies. The maps identify mutations that escape antibody binding, including a single mutation that escapes both antibodies in the Regeneron antibody cocktail. Many of the mutations that escape single antibodies are circulating in the human population. Science , this issue p. 850
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Escape maps are consistent with viral mutations selected in cell culture and a persistently infected patient. (A) Viral escape mutations selected by Regeneron with spike-pseudotyped VSV in cell culture in the presence of antibody (12). (B) Escape maps like those in Fig. 1A, but showing only mutations accessible by single-nucleotide changes to the Wuhan-Hu-1 sequence, with nongray colors indicating mutations in cell culture (red), the infected patient (blue), or both (purple). Figure S5 shows these maps colored by how mutations affect ACE2 affinity or RBD expression. (C) Dynamics of RBD mutations in a patient treated with REGN-COV2 at day 145 of infection (black dot-dash vertical line). E484A rose in frequency in linkage with F486I, but because E484A is not an escape mutation in our maps, it is not shown in other panels. See also fig. S4. (D) The escape mutations that arise in cell culture and the infected patient are single-nucleotide–accessible and escape antibody binding without imposing a large cost on ACE2 affinity [as measured using yeast display (7)]. Each point is a mutation, with shape and color indicating whether it is accessible and selected during viral growth. Points farther to the right on the x axis indicate stronger escape from antibody binding; points higher up on the y axis indicate higher ACE2 affinity.](https://figures.cochat.ai/paper-figures/91cf075ab18741e0a80bfb01ad2b708a/prospective-mapping-of-viral-mutations-that-escape-antibodies-used-to-treat-figure-2.jpg)

![Fig. 4 Structural context of escape mutations. (A) Escape maps projected on antibody-bound RBD structures. [REGN10933 and REGN10987: Protein Data Bank (PDB) ID 6XDG (11); LY-CoV016: PDB ID 7C01 (13)]. Antibody heavy- and light-chain variable domains are shown as blue cartoons, and the RBD surface is colored to indicate how strongly mutations at that site mediate escape (white indicates no escape, red indicates strongest escape site for that antibody or cocktail). Sites where no mutations are functionally tolerated are colored gray. (B) For each antibody, sites were classified as direct antibody contacts (non-hydrogen atoms within 4 Å of antibody), antibody-proximal (4 to 8 Å), or antibody-distal (>8 Å). Each point indicates a site, classified as escape (red) or non-escape (black). The dashed gray line indicates the cutoff used to classify sites as escape or non-escape (see materials and methods for details). Red and black numbers indicate how many sites in each category are escape or non-escape sites, respectively. Interactive visualizations are at https://jbloomlab.github.io/SARS-CoV-2-RBD_MAP_clinical_Abs/, and hypothesized mechanisms of escape and additional structural details for labeled points are shown in fig. S6.](https://figures.cochat.ai/paper-figures/854cbba408614d74b93381682c26dd9e/prospective-mapping-of-viral-mutations-that-escape-antibodies-used-to-treat-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A475V is resistant to class 1 antibodies (structurally defined as described29); E484K and Q493R are resistant to class 2 antibodies7,8,12,13,29,30,32,33; while R346S, N439K, and N440K are resistant to class 3 antibodies7,8,12,13,29,33.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several of the RBD mutations directly affect angiotensin-converting enzyme 2 (ACE2) receptor-binding affinity, which may affect infectivity, viral load, or transmissibility.11, 12, 13, 14”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations found in emergent S variants decrease sensitivity to neutralization by mAbs, convalescent plasma, and sera from vaccinated individuals (27, 37, 58, 61–70).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The B.1.1.7, B.1.351, and P.1 lineages all harbor a N501Y mutation in the RBD, which increases the affinity for the ACE2 receptor (57, 58), and a D614G mutation, which increases virion spike density, infectivity, and transmissibility (59, 60).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We tested four clinically approved monoclonal antibodies that target the RBD 18,19 (bamlanivimab (LY-CoV555), etesevimab (LY-CoV016), casirivimab (REGN10933) and imdevimab (REGN10987))”
From Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization (2021) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability
Katoh, K., & Standley, D. M. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst010 · Cited by 46,209
fastp: an ultra-fast all-in-one FASTQ preprocessor
Chen, S., Zhou, Y., Chen, Y., & Gu, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty560 · Cited by 29,721
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM
Li, H. (2013) · DROPS (Schloss Dagstuhl – Leibniz Center for Informatics) · doi:10.48550/arxiv.1303.3997 · Cited by 5,159
Aligning sequence reads, clone sequences and assembly con*gs with BWA-MEM
Li, H. (2014) · arXiv (Cornell University) · doi:10.6084/m9.figshare.963153.v1 · Cited by 4,932
Structural basis of receptor recognition by SARS-CoV-2
Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661
Snakemake—a scalable bioinformatics workflow engine
Köster, J., & Rahmann, S. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts480 · Cited by 2,780
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535
Detection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510
Research works printed but not linked: 2
- 10.1016/j.cell.2020.02.058 · doi:10.1016/j.cell.2020.02.058 · Paper page
- Regeneron Pharmaceuticals Inc. “Regeneron’s casirivimab and imdevimab antibody cocktail for COVID-19 is first combination therapy to receive FDA emergency use authorization ” press release (21 November 2020); https://investor.regeneron.com/news-releases/news-release-details/regenerons-regen-cov2-first-antibody-cocktail-covid-19-receive/.
Cited by
Items 701–750 of 750
Singh, A., Verma, A. K., Pandey, A. K., & Bajpai, J. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815123197123010008
Spatial and Temporal Analysis of SARS-CoV-2 Genome Evolutionary PatternsPreprint
Gupta, S., Gupta, D., & Bhatnagar, S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.21.545910
Yi, C., Sun, X., Lin, Y., Gu, C., Ding, L., Lu, X., Yang, Z. R., Zhang, Y., Ma, L., Gu, W., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16815705
Yi, C., Sun, X., Lin, Y., Gu, C., Ding, L., Lu, X., Yang, Z. R., Zhang, Y., Ma, L., Gu, W., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16815708
Yi, C., Sun, X., Lin, Y., Gu, C., Ding, L., Lu, X., Yang, Z. R., Zhang, Y., Ma, L., Gu, W., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16815702
Ketaren, N. E., Mast, F. D., Fridy, P. C., Olivier, J. P., Sanyal, T., Sali, A., Chait, B. T., Rout, M. P., & Aitchison, J. D. (2024) · doi:10.7554/elife.89423.2
SARS-CoV-2 epidemiology, kinetics, and evolution: a narrative reviewPreprint
Alizon, S., & Sofonea, M. T. (2024) · doi:10.31219/osf.io/etv85
D’Agostino, M. R., Li, J., Zhang, Z., Gu, J., Marzok, A., Ang, J. C., Bujold, K. E., Afkhami, S., Xia, X., Li, Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.31.596896
Self-citationVIEPred: Predicting Viral Immune Evasion with Multimodal Representation Learning
Liang, B., Wang, N., Huang, H., Hou, Y., & Qiang, X. (2024) · Journal of Physics Conference Series · doi:10.1088/1742-6596/2868/1/012029 · Cited by 1
Backstage Heroes—Yeast in COVID-19 Research
Grabiński, W., Karachitos, A., & Kicińska, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312661 · Cited by 1
Alshahrani, M., Parikh, V., Foley, B., & Verkhivker, G. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.15.649027
Dissecting serum polyclonal antibody escape to SARS-CoV-2 variants by deep mutational learning
Shlesinger, D., Sadílek, V., Minot, M., Stamkopoulos, E., Bikias, T., Kuhn, R., Agrafiotis, A., Taft, J. M., Yermanos, A., & Reddy, S. T. (2026) · Cell Reports Methods · doi:10.1016/j.crmeth.2026.101417 · Cited by 1
Lee, C. Y., Huang, C.-W., Falco, L. D., Minhat, R. A., Traversier, A., Wang, B., Salleh, S. N. M., Ngoh, E. Z. X., Huang, Y., Kim, J., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112687
Jung, I., Sriramulu, D. K., Yoon, J. H., Lee, J., Kim, T. W., Kweon, D., Lee, S., & Jung, S. T. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c01169
Wang, C., Liu, Z., Mei, J., Jia, M., Ahmad, S., & Ai, H. (2025) · Physical Chemistry Chemical Physics · doi:10.1039/d5cp01710f
Grasemann, L., Han, J., Tischler, J., Arefi, F., Castillo, M. A. G., Irvine, E. B., Chen, N., Reddy, S. T., & Maerkl, S. J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.23.678000
A High-Resolution Approach to Mapping Spike Protein Evolution for Advancing Antibody Therapy DesignPreprint
Bhatti (2025) · Research Square · doi:10.21203/rs.3.rs-7753519/v1
What Has SARS-CoV-2 Taught Us About Evolution?
Liu, Y. (2025) · Cureus · doi:10.7759/cureus.94502 · Cited by 1
Modeling the Mutational Effects on Biochemical Phenotypes of SARS-CoV-2 Using Molecular Fields
Wang, B., & Xi, Z. (2025) · Biomolecules · doi:10.3390/biom15111538
“For the antibody combination, the experimental data used by the escape calculator were drawn from previously published deep mutational scanning studies against a panel of 33 neutralizing antibodies [25,46–50].”
InfluentialHelix α1 of human ACE2 mimics dsDNA and Spike of SARS-CoV-2 binds DNA
Bangaru, M. L. Y., & Raghavendra, N. K. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.153020
Additional file 2 of A phenomics approach for antiviral drug discovery
Rietdijk, J., Tampere, M., Pettke, A., Georgiev, P., Lapins, M., Berglund, U. W., Spjuth, O., Puumalainen, M.-R., & Puigvert, J. C. (2021) · Figshare · doi:10.6084/m9.figshare.15088506
Schröder, S., Richter, A., Veith, T., Emanuel, J., Gudermann, L., Friedmann, K., Jeworowski, L. M., Mühlemann, B., Jones, T. C., Müller, M. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26637489
Additional file 1 of A phenomics approach for antiviral drug discovery
Rietdijk, J., Tampere, M., Pettke, A., Georgiev, P., Lapins, M., Berglund, U. W., Spjuth, O., Puumalainen, M.-R., & Puigvert, J. C. (2021) · Figshare · doi:10.6084/m9.figshare.15088503
Yi, C., Sun, X., Lin, Y., Gu, C., Ding, L., Lu, X., Yang, Z., Zhang, Y., Ma, L., Gu, W., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16815699
Li, L., Gao, M., Jiao, P., Zu, S., Deng, Y.-Q., Wan, D., Cao, Y., Duan, J., Aliyari, S. R., Li, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19783635
Self-citationHumoral epitope dominance and immune imprinting by SARS ‐ CoV ‐1 and SARS ‐ CoV ‐2 vaccines
Burnett, D. L., Moxon, A., Aggarwal, A., Jackson, K., Cotter, C. A., Akerman, A., Russell, A. J., KALMAN, R., Langley, D. B., Henry, J. Y., et al. (2026) · Immunology and Cell Biology · doi:10.1111/imcb.70072
Martínez-Guevara, J. L., Lai, T. Y., Mishra, M., Slamanig, S., González‐Domínguez, I., Abdeljawad, A., Hoang, M. T., Singh, G., Kowdle, S., Benhur, L., et al. (2026) · Vaccines · doi:10.3390/vaccines14020138
Ayres, F., Lambson, B. E., Mkhize, N. N., Makhado, Z., Mhlanga, D., Serage, R., Moore, P. L., Wibmer, C. K., & Moyo-Gwete, T. (2026) · Structure · doi:10.1016/j.str.2026.01.006
Kotzen, B., Gurev, S. F., Youssef, N., Jaimes, J. A., Luban, J., Marks, D. S., Seaman, M. S., & Lemieux, J. E. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.26.706090
MetaEntropy: Functional Shannon Entropy for Virome Mutational Analysis
Jones, L. R., & Manrique, J. M. (2026) · doi:10.32614/cran.package.metaentropy
Jaiswal, D., Altomare, C. G., Adelsberg, D. C., Sapse, I. A., Krammer, F., Simon, V. R., Ellebedy, A. H., & Bajic, G. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.03.709398
The role of O-GlcNAcylation in the pathophysiology of Systemic Lupus Erythematosus
Galli, G. (2022) · theses.fr (ABES) · doi:10.70675/db863337z7c69z4a5dz9e94z7163b54542ee
Modeling and Standard Binding Free Energy Calculations of Complex Biological Objects
Blazhynska, M. (2023) · theses.fr (ABES) · doi:10.70675/48e8ac59z3fecz4841za036z40e6a446b0cc
Seroepidemiology of emerging viruses in Bolivia
Jordan, L. I. (2023) · theses.fr (ABES) · doi:10.70675/1070f335z49aaz4d85zb796z713dd35bc6fc
Hirata, Y., Takahashi, K., Iwamoto, N., Jeong, Y. D., Miyamoto, S., Kawasaki, J., Harrison, M. T., Mine, S., Iida, S., Saito, S., et al. (2026) · medRxiv · doi:10.64898/2026.04.14.26350918
Xu, K., Pei, J., Wang, C. R., Guo, J., Chen, X.-Q., & Shen, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1837533
Jaiswal, D., Altomare, C. G., Adelsberg, D. C., Sapse, I. A., Krammer, F., Simon, V. R., Ellebedy, A. H., & Bajic, G. (2026) · eLife · doi:10.7554/elife.111137
Jaiswal, D., Altomare, C. G., Adelsberg, D. C., Sapse, I. A., Krammer, F., Simon, V. R., Ellebedy, A. H., & Bajic, G. (2026) · eLife · doi:10.7554/elife.111137.1
Han, J., Grasemann, L., Tischler, J., Arefi, F., castillo, M. M., Irvine, E. B., Chen, N., Reddy, S. T., & Maerkl, S. J. (2026) · Cell Systems · doi:10.1016/j.cels.2026.101713
Leka, K., Mamede, L., Lesenfants, C., Robbiano, S., Vandeberg, E., Hamann, C., Frédérich, M., Garigliany, M., & Ledoux, A. (2026) · ACS Omega · doi:10.1021/acsomega.5c12922
Genomic surveillance of SARS-CoV-2: a resource-efficient wastewater-based workflow
Manrique, J. M., & Jones, L. R. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12220-z
Zrelovs, Ņ., Oļševskis, E., Perevoščikovs, J., Silamiķelis, I., Jakovele, A., Lamberga, K., Bērziņš, A., Brīvība, M., & Kloviņš, J. (2026) · Virus Evolution · doi:10.1093/ve/veag038
Machine Learning in Molecular Dynamics Applications in Medicinal Chemistry
Amin, S. A., Kar, S., & Piotto, S. (2026) · Royal Society of Chemistry eBooks · doi:10.1039/9781837070206-00153
Chowdhury, R., Vaishnavey, S. R., Dey, S., Ferdous, S., Danurdoro, R., & Zeller, M. A. (2026) · Bioinformatics · doi:10.1093/bioinformatics/btag529
Shao, C., Fu, J., Deng, F., Yu, H., Fan, H., Chen, Y., Xu, K., Wei, M., 贾斯月, Jia, X., et al. (2026) · Microorganisms · doi:10.3390/microorganisms14091872
“The Omicron variant and its descendants, particularly within the receptor-binding domain (RBD), have acquired numerous amino acid substitutions that alter angiotensin-converting enzyme 2 (ACE2) binding and evade neutralizing antibodies [4–8].”
Self-citationCamelid VHHs as a Versatile Platform for Combating Viral Infections
Mufrrih, M., & Alandijany, T. A. (2026) · Pharmaceuticals · doi:10.3390/ph19091408
“Escape is especially plausible when a monovalent VHH relies on a single exposed, variable epitope [124–126].”
Javdan, S., Moghim, S., Rostami, F., Shirani, K., Nasrabadi, E. N., & Esfahani, B. N. (2026) · BioMed Research International · doi:10.1155/bmri/1239885
“A region of the SARS-CoV-2 spike gene was amplified by real-time PCR using the primers F (5 ′ -CCCTGTTGCTATTCATGCAG-3 ′ ) and R (5 ′ -CCCTATTAAACAGCCTGCAC-3 ′ ) [19].”
Hard, R. L., Ko, Y. S., Parkinson, J., & Wang, W. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00213
Epistasis and the changing fitness landscapes of SARS-CoV-2
Sesta, L., & Neher, R. A. (2026) · Genetics · doi:10.1093/genetics/iyag227 · Cited by 1
Clonotype specificity distinguishes epitope-tailored and permissive somatic hypermutationPreprint
Rao, V. N., Bonnettaz, B., Civljak, A., Abbad, A., Krammer, F., Coelho, C. H., & Bajic, G. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.10.758199
Metadata
- Authors
- Starr, T. N., Greaney, A. J., Addetia, A., Hannon, W. W., Choudhary, M. C., Dingens, A. S., Li, J. Z., & Bloom, J. D.
- Affiliations
- Fred Hutch Cancer Center (US)
- University of Washington (US)
- Brigham and Women's Hospital (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Bloom, Jesse D.
- ORCID
- Venue
- Science
- Published
- 2021-02-19
- Volume
- 371
- Issue
- 6531
- Pages
- 850-854
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7963219
- OpenAlex
- W3125266951
- Cited by
- 743
- References
- 40
- Citations by year
- 2026: 31 · 2025: 37 · 2024: 56 · 2023: 104 · 2022: 232 · 2021: 279
- FWCI
- 53.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by)
- Funders
- Howard Hughes Medical Institute (Investigator)
- National Institute of Allergy and Infectious Diseases (R01AI127893, R01AI141707)
- Bill and Melinda Gates Foundation (INV-004949)
- Damon Runyon Cancer Research Foundation (DRG-2381-19)
- Massachusetts Consortium for Pathogen Readiness
- Washington Research Foundation (Innovation Fellow)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Keywords
- SARS-CoV-2, COVID-19 pandemic, antibody escape, receptor binding domain, viral mutations, monoclonal antibodies, antibody binding, viral surveillance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.